Connection

SETH LERNER to Immunohistochemistry

This is a "connection" page, showing publications SETH LERNER has written about Immunohistochemistry.
Connection Strength

0.275
  1. Expression of estrogen receptors-alpha and -beta in bladder cancer cell lines and human bladder tumor tissue. Cancer. 2006 Jun 15; 106(12):2610-6.
    View in: PubMed
    Score: 0.032
  2. Correlation of cyclooxygenase-2 expression with molecular markers, pathological features and clinical outcome of transitional cell carcinoma of the bladder. J Urol. 2003 Sep; 170(3):985-9.
    View in: PubMed
    Score: 0.027
  3. Association of p53 and p21 expression with clinical outcome in patients with carcinoma in situ of the urinary bladder. Urology. 2003 Jun; 61(6):1140-5.
    View in: PubMed
    Score: 0.026
  4. Cyclooxygenase-2 is highly expressed in carcinoma in situ and T1 transitional cell carcinoma of the bladder. J Urol. 2003 Mar; 169(3):938-42.
    View in: PubMed
    Score: 0.026
  5. Predictive value of expression of transforming growth factor-beta(1) and its receptors in transitional cell carcinoma of the urinary bladder. Cancer. 2001 Sep 15; 92(6):1475-83.
    View in: PubMed
    Score: 0.023
  6. E-cadherin immunostaining of bladder transitional cell carcinoma, carcinoma in situ and lymph node metastases with long-term followup. J Urol. 2001 May; 165(5):1473-9.
    View in: PubMed
    Score: 0.023
  7. Prognostic value of P53 nuclear accumulation and histopathologic features in T1 transitional cell carcinoma of the urinary bladder. Urology. 2000 Nov 01; 56(5):735-40.
    View in: PubMed
    Score: 0.022
  8. Positive association of collagen type I with non-muscle invasive bladder cancer progression. Oncotarget. 2016 Dec 13; 7(50):82609-82619.
    View in: PubMed
    Score: 0.017
  9. Prognostic Significance of Neutrophilic Infiltration in Benign Lymph Nodes in Patients with Muscle-invasive Bladder Cancer. Eur Urol Focus. 2017 02; 3(1):130-135.
    View in: PubMed
    Score: 0.016
  10. The angiopoietin-TIE2 pathway is a potential therapeutic target in urothelial carcinoma. Anticancer Res. 2014 Jul; 34(7):3377-82.
    View in: PubMed
    Score: 0.014
  11. The preclinical activity of lenalidomide in indolent urothelial carcinoma. Anticancer Res. 2014 Jul; 34(7):3383-9.
    View in: PubMed
    Score: 0.014
  12. A first in human phase 1 study of CG0070, a GM-CSF expressing oncolytic adenovirus, for the treatment of nonmuscle invasive bladder cancer. J Urol. 2012 Dec; 188(6):2391-7.
    View in: PubMed
    Score: 0.013
  13. Multi-institutional validation of the predictive value of Ki-67 labeling index in patients with urinary bladder cancer. J Natl Cancer Inst. 2009 Jan 21; 101(2):114-9.
    View in: PubMed
    Score: 0.010
  14. Multiple biomarkers improve prediction of bladder cancer recurrence and mortality in patients undergoing cystectomy. Cancer. 2008 Jan 15; 112(2):315-25.
    View in: PubMed
    Score: 0.009
  15. Level of retinoblastoma protein expression correlates with p16 (MTS-1/INK4A/CDKN2) status in bladder cancer. Oncogene. 1999 Feb 04; 18(5):1197-203.
    View in: PubMed
    Score: 0.005
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.